Jumi Yi1, James B Wood2, C Buddy Creech3, Derek Williams4, Natalia Jimenez-Truque3, Inci Yildirim5, Bethany Sederdahl6, Michael Daugherty6, Laila Hussaini6, Mohamed Munye6, Kay M Tomashek7, Christopher Focht8, Nora Watson8, Evan J Anderson6, Isaac Thomsen9. 1. Emory University School of Medicine and Children's Healthcare of Atlanta; Atlanta, GA; University of California San Francisco, San Francisco, CA. 2. Indiana University School of Medicine, Vanderbilt University Medical Center, Nashville, TN; Vanderbilt Vaccine Research Program, Department of Pediatrics and Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN. 3. Vanderbilt Vaccine Research Program, Department of Pediatrics and Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN. 4. Vanderbilt Vaccine Research Program, Department of Pediatrics and Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN; Division of Pediatric Hospital Medicine, Vanderbilt University Medical Center, Nashville, TN. 5. Emory University School of Medicine and Children's Healthcare of Atlanta; Atlanta, GA; Yale School of Medicine, Department of Pediatrics and Section of Pediatric Infectious Diseases & Global Health, New Haven, CT. 6. Emory University School of Medicine and Children's Healthcare of Atlanta; Atlanta, GA. 7. National Institutes of Health: Division of Microbiology and Infectious Diseases (DMID), Bethesda, MD. 8. Emmes Corporation, Rockville, MD. 9. Vanderbilt Vaccine Research Program, Department of Pediatrics and Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN. Electronic address: isaac.thomsen@vumc.org.
Abstract
OBJECTIVES: To understand the epidemiology of acute hematogenous osteomyelitis and septic arthritis, including clinical and demographic features, microbiology, treatment approaches, treatment-associated complications, and outcomes. STUDY DESIGN: Retrospective cohort study of 453 children with acute hematogenous osteomyelitis and/or septic arthritis from 2009 to 2015. RESULTS: Among the 453 patients, 218 (48%) had acute hematogenous osteomyelitis, 132 (29%) had septic arthritis, and 103 (23%) had concurrent acute hematogenous osteomyelitis/septic arthritis. Treatment failure/recurrent infection occurred in 41 patients (9%). Patients with concurrent acute hematogenous osteomyelitis/septic arthritis had longer hospital stays, longer duration of antibiotic therapy, and were more likely to have prolonged bacteremia and require intensive care. Staphylococcus aureus was identified in 228 (51%) patients, of which 114 (50%) were methicillin-resistant S aureus. Compared with septic arthritis, acute hematogenous osteomyelitis and concurrent acute hematogenous osteomyelitis/septic arthritis were associated with higher odds of treatment failure (OR, 8.19; 95% CI, 2.02-33.21 [P = .003]; and OR, 14.43; 95% CI, 3.39-61.37 [P < .001], respectively). The need for more than 1 surgical procedure was also associated with higher odds of treatment failure (OR, 2.98; 95% CI, 1.18-7.52; P = .021). Early change to oral antibiotic therapy was not associated with treatment failure (OR, 0.64; 95% CI, 0.24-1.74; P = .386). Most (73%) medically attended treatment complications occurred while on parenteral therapy. CONCLUSIONS: Musculoskeletal infections are challenging pediatric infections. S aureus remains the most common pathogen, with methicillin-resistant S aureus accounting for 25% of all cases. Concurrent acute hematogenous osteomyelitis/septic arthritis is associated with more severe disease and worse outcomes. Fewer treatment-related complications occurred while on oral therapy. Early transition to oral therapy was not associated with treatment failure.
OBJECTIVES: To understand the epidemiology of acute hematogenous osteomyelitis and septic arthritis, including clinical and demographic features, microbiology, treatment approaches, treatment-associated complications, and outcomes. STUDY DESIGN: Retrospective cohort study of 453 children with acute hematogenous osteomyelitis and/or septic arthritis from 2009 to 2015. RESULTS: Among the 453 patients, 218 (48%) had acute hematogenous osteomyelitis, 132 (29%) had septic arthritis, and 103 (23%) had concurrent acute hematogenous osteomyelitis/septic arthritis. Treatment failure/recurrent infection occurred in 41 patients (9%). Patients with concurrent acute hematogenous osteomyelitis/septic arthritis had longer hospital stays, longer duration of antibiotic therapy, and were more likely to have prolonged bacteremia and require intensive care. Staphylococcus aureus was identified in 228 (51%) patients, of which 114 (50%) were methicillin-resistant S aureus. Compared with septic arthritis, acute hematogenous osteomyelitis and concurrent acute hematogenous osteomyelitis/septic arthritis were associated with higher odds of treatment failure (OR, 8.19; 95% CI, 2.02-33.21 [P = .003]; and OR, 14.43; 95% CI, 3.39-61.37 [P < .001], respectively). The need for more than 1 surgical procedure was also associated with higher odds of treatment failure (OR, 2.98; 95% CI, 1.18-7.52; P = .021). Early change to oral antibiotic therapy was not associated with treatment failure (OR, 0.64; 95% CI, 0.24-1.74; P = .386). Most (73%) medically attended treatment complications occurred while on parenteral therapy. CONCLUSIONS: Musculoskeletal infections are challenging pediatric infections. S aureus remains the most common pathogen, with methicillin-resistant S aureus accounting for 25% of all cases. Concurrent acute hematogenous osteomyelitis/septic arthritis is associated with more severe disease and worse outcomes. Fewer treatment-related complications occurred while on oral therapy. Early transition to oral therapy was not associated with treatment failure.
Authors: Alan D Tice; Susan J Rehm; Joseph R Dalovisio; John S Bradley; Lawrence P Martinelli; Donald R Graham; R Brooks Gainer; Mark J Kunkel; Robert W Yancey; David N Williams Journal: Clin Infect Dis Date: 2004-05-26 Impact factor: 9.079
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Cynthia G Whitney; Tamar Pilishvili; Monica M Farley; William Schaffner; Allen S Craig; Ruth Lynfield; Ann-Christine Nyquist; Kenneth A Gershman; Marietta Vazquez; Nancy M Bennett; Arthur Reingold; Ann Thomas; Mary P Glode; Elizabeth R Zell; James H Jorgensen; Bernard Beall; Anne Schuchat Journal: Lancet Date: 2006-10-28 Impact factor: 79.321
Authors: James B Wood; Gregory P Fricker; Susan E Beekmann; Philip Polgreen; C Buddy Creech Journal: J Pediatric Infect Dis Soc Date: 2018-08-17 Impact factor: 3.164